Deep genomic analysis of solid tumours
Celldx offers comprehensive tissue-based molecular profiling for solid tumours, aiming to personalise therapy options. In addition to genetic analysis, Celldx provides valuable insights into the potential benefits of immune checkpoint inhibitors.
ABOUT Celldx
Celldx customises cancer treatment by identifying genetic alterations suitable for targeted therapies. Furthermore, immunostaining is conducted on tissue samples to assess PD-L1 suitability, in conjunction with tumour mutational burden and MMR status.
Celldx provides deep molecular analysis for patients with advanced cancers.
COMPREHENSIVE
Biomarker Based Drug Indications (Examples)
FAQ
Which analytes are included?
SNVs, INDELs, CNAs, Fusions, TMB, PD-L1, MMR, HRD (Homologous recombination deficiency).
Is celldx suited as a companion diagnostic tool?
Yes, Celldx can provide information if a target alteration is present. Evaluation of therapies in the need of companion diagnostics across several cancer indications is available as well as clinical trial matching across all solid tumours.
Is celldx of advantage when selecting an immunotherapy?
Celldx provides informed decisions if an immunotherapy is beneficial using genomic signatures like tumour mutational burden (TMB) and PD-L1 status via immunostaining.
CONTACT
Cancer Profiling Australia
903/50 Clarence Street,
SYDNEY NSW 2000
PH +61 1300 282 482
FAX +61 2 8088 7097
Email: info@cancerprofiling.com.au